[Insight] From Approvals to Recurring Revenue…Medical AI Valuations Are Changing
Capital markets are changing how they assess South Korean medical artificial intelligence companies. A few years ago, overseas regulatory milestones, including U.S. Food and Drug Administration (FDA) authorizations and European CE marking, along with supply contracts with major hospitals, were considered key drivers of share prices. The ability of a technology company to enter a tightly regulated…
South Korean medical AI firms are experiencing a shift in how capital markets evaluate their worth, with a growing focus on actual usage and revenue generation rather than just regulatory approvals and contracts. In the past, the feat of gaining FDA authorizations, CE marking in Europe, and partnerships with major hospitals were considered major milestones.
Now, investors scrutinize how widely authorized products are utilized in clinical practice and the resulting revenue. Remote patient monitoring metrics now include installed beds and hospital penetration, while medical imaging AI is judged by the number of examinations analyzed and ongoing usage volumes. Overseas operations require attention to reimbursement arrangements, claims submission, contract renewal rates, and revenue recognition timing.
A recent IBK Securities analysis of Seers Technology highlighted the importance of expanding domestic monitoring beds and the revenue timing from its UAE business. However, investors must differentiate between supply contracts and actual operations, as a company's installed beds and contracted hospitals may not always translate into paid services or consistent usage.
Coreline Soft serves as an example of this shift in medical imaging AI. The company secured 77 new contracts in Germany by July, a significant rise from just 10 during the entire previous year. This surge can be attributed to the integration of low-dose computed tomography (CT) lung cancer screening, which is now covered by Germany's statutory health insurance system.
For core products to thrive in this new market, they must seamlessly integrate with Picture Archiving and Communication Systems (PACS) and reading workflows, enabling consistent comparisons between earlier and current examinations. As Coreline Soft installs more products, revenue is projected to shift from one-time sales to recurring income, with per-examination revenue expected to emerge next year.
In the U.S., investors are increasingly monitoring usage and subscription longevity alongside new regulatory approvals. Coreline Soft reported that its subscription relationship with 3DR Labs has lasted four years, with annual usage increasing by 60%. Additionally, overseas revenue has surged 123% year-on-year, accounting for 61.9% of total revenue, while operating losses have reduced by 21%.
Investors should carefully differentiate between contract counts, installed sites, active sites, and AI analysis volumes, as each reflects a distinct aspect of a company's progress. Assessing recurring revenue requires examining factors such as regulatory authorization, contracting, installation, actual usage, reimbursement, billing, contract renewals, and further product deployments.
Ultimately, the value of a medical AI company is determined by its performance across all stages, from obtaining regulatory approval to converting usage into sustainable revenue.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
